Development of a new series of aryl ureido derivatives as anticancer agents against breast cancer cells

Abstract

Breast cancer is the second cause of cancer mortality worldwide in humans and half of all tumours in dogs and there is an unmet need for novel anticancer agents. I have developed a new series of aryl ureido derivatives as anticancer agents. These compounds have a strong antiproliferative effect against canine breast cancer CMT-U27 cells at concentrations (1-10 μM) comparable to drugs that have already been used in chemotherapy such as gefitinib, soferanib and lapatinib. These results suggest that aryl ureido derivatives were potent inhibitors of proliferation of breast cancer cells. © PHARMAKON-Press.